DBV Technologies downgraded by Societe Generale
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Societe Generale downgraded DBV Technologies from Hold to Sell
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
| 9/14/2021 | Hold → Buy | Societe Generale |
Châtillon, France, November 11, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one (1) ordinary share to a new ADS Ratio of one (1) ADS to five (5) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on or
Châtillon, France, November 6, 2024 DBV Technologies Reports Third Quarter 2024 Financial Results DBV closes Q3 2024 with a cash balance of $46.4 million; cash runway into Q1 2025 DBV Technologies (TRQX:DBVp), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter of 2024. The quarterly and nine months financial statements were approved by the Board of Directors on November 6, 2024. Financial Highlights for the third quarter Ended September 30, 2024 The Company's interim condensed consolidated financial statements for the nine months ended September 30, 2024, are prepared in accordance with accounting principles generally ac
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
F-6 POS - DBV Technologies S.A. (0001613780) (Subject)
8-K - DBV Technologies S.A. (0001613780) (Filer)
10-Q - DBV Technologies S.A. (0001613780) (Filer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
4 - DBV Technologies S.A. (0001613780) (Issuer)
Societe Generale upgraded DBV Technologies from Hold to Buy
Goldman downgraded DBV Technologies from Neutral to Sell
Goldman downgraded DBV Technologies from Buy to Neutral and set a new price target of $1.50 from $6.00 previously
Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024Appointment of Robert Pietrusko, PharmD to Chief Regulatory OfficerQ1 2024 closes with a cash balance of $101.5 million DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the first quarter 2024. The quarterly financial statements were approved by the Board of Directors on May 7, 2024. Recent
Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023. An experienced financial and operations executive, Virginie will report directly to Daniel Tassé, Chief Executive Officer, and serve as a member of the Executive Committee. "I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization," said Daniel Tassé, Chief Executive Officer, DBV Tech
Montrouge, France, October 3, 2022 DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that Mr. Timothy E. Morris, Independent Director and Member of the Audit Committee of the Board of Directors ("the Board"), was appointed as Chairperson of the Board's Audit Committee in replacement of Ms. Viviane Monges, who resigned from the Board effective October 3, 2022. DBV also announced the Board's provisional appointment of Ms. Daniele Guyot-Caparros as Independent Director to fill Ms. Monges' vacancy, effective October
Châtillon, France, October 22, 2024 DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe DBV to pursue an Accelerated Approval pathway for toddlers ages 1 – 3 years-old BLA submission under Accelerated Approval is subject to completion of a six-month supplemental safety study in toddlers to be initiated in Q2 2025VITESSE Phase 3 study evaluating the Viaskin Peanut patch in children ages 4 – 7 years-old exceeded enrollment goals; Topline results on track for 4Q 2025 European Medicines Agency (EMA) scientific advice confirms registration path for a Marketing Authorization Application (MAA) with the modified Viaskin peanut patch for a 1 – 7
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT ToddlersDBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 DBV Technologies (Euronext: DBV – ISIN: FR0010417
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. Interested participants may access this call via the below teleconferencing numbers and asking to join the DBV Technologies call: United States: +1-877-346-6112International: +1-848-280-6350 A live webcast of the call will be a
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
SC 13G/A - DBV Technologies S.A. (0001613780) (Subject)
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 124.3% to $0.98 during Thursday's pre-market session. The company's market cap stands at $4.9 million. Virax Biolabs Group (NASDAQ:VRAX) stock increased by 116.82% to $2.32. The company's market cap stands at $5.4 million. iSpecimen (NASDAQ:ISPC) shares increased by 36.65% to $0.44. The market value of their outstanding shares is at $4.3 million. 60 Degrees (NASDAQ:SXTP) shares moved upwards by 28.26% to $0.37. The company's market cap stands at $4.4 million. CERo Therapeutics Hldgs (NASDAQ:CERO) shares rose 27.08% to $1.15. The market value of their outstanding shares is at $17.3 million. OneMedNet (NASDAQ:ONMD) stock incre
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, previously announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change") to be effective on or about June 3rd, 2024. The Company now anticipates that the ADS Ratio Ch
DBV Technologies Announces Plan to Implement ADS Ratio ChangeDBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares (the "ADS Ratio"), nominal value €0.10 (ten cents) per share, from the current ADS Ratio of one (1) ADS to one-half (1/2) of one (1) ordinary share to a new ADS Ratio of one (1) ADS to one (1) ordinary share (the "ADS Ratio Change"). The Company anticipates that the ADS